{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:07:48Z","timestamp":1775696868492,"version":"3.50.1"},"reference-count":20,"publisher":"Galenos Yayinevi","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.4274\/tjo.galenos.2021.25488","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T06:37:16Z","timestamp":1661409436000},"page":"262-269","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the Use of Brinzolamide-Brimonidine Fixed Combination in Maximum Medical Therapy"],"prefix":"10.4274","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-7092","authenticated-orcid":false,"given":"Oya","family":"Tekeli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4654-0657","authenticated-orcid":false,"given":"Helin Ceren","family":"K\u00f6se","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1442-9071.2012.02773.x","article-title":"Definition of glaucoma: clinical and experimental concepts","volume":"40","author":"Casson","year":"2012","unstructured":"1. Casson RJ, Chidlow G, Wood JP, Crowston JG, Goldberg I. Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol. 2012;40:341-349.","journal-title":"Clin Exp Ophthalmol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/aos.12203","article-title":"Factors associated with lifetime risk of open-angle glaucoma blindness","volume":"92","author":"Peters","year":"2014","unstructured":"2. Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol. 2014;92:421-425.","journal-title":"Acta Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. No authors listed. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000;130:429-440.","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"ref3","unstructured":"4. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd ed. Savona: Editrice Dogma S.r.l; 2008."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","unstructured":"5. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.","journal-title":"Arch Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","article-title":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options","volume":"101","author":"authors listed","year":"2017","unstructured":"6. No authors listed. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017;101:130-195.","journal-title":"Br J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.2147\/OPTH.S228777","article-title":"Maximum Medical Therapy: Brinzolamide\/Brimonidine And Travoprost\/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension","volume":"13","author":"Lerner","year":"2019","unstructured":"7. Lerner SF, Oddone F, Lu DW, Sanseau A, Guarro M, Ridolfi A, Hubatsch D. Maximum Medical Therapy: Brinzolamide\/Brimonidine And Travoprost\/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension. Clin Ophthalmol. 2019;13:2411-2419.","journal-title":"Clin Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1185\/03007990903260129","article-title":"Glaucoma medication persistence with a fixed combination versus multiple bottles","volume":"25","author":"Higginbotham","year":"2009","unstructured":"8. Higginbotham EJ, Hansen J, Davis EJ, Walt JG, Guckian A. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009;25:2543-2547.","journal-title":"Curr Med Res Opin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9570.1000248","article-title":"Adherence and persistence with glaucoma therapy: brimonidine\/ timolol versus dorzolamide\/timolol and various two-bottle combinations","volume":"3","author":"Schwartz","year":"2012","unstructured":"9. Schwartz G, Burk C, Bennett T, Patel VD. Adherence and persistence with glaucoma therapy: brimonidine\/ timolol versus dorzolamide\/timolol and various two-bottle combinations. J Clin Exp Ophthalmol. 2012;3:1-6.","journal-title":"J Clin Exp Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00055735-199704000-00010","article-title":"The potential systemic effect of topically applied beta-blockers in glaucoma therapy","volume":"8","author":"Taniguchi","year":"1997","unstructured":"10. Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol. 1997;8:55-58.","journal-title":"Curr Opin Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrop for glaucoma. Ophthalmic Surg. 1995;26:233-236.","DOI":"10.3928\/1542-8877-19950501-14"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/00061198-199201020-00012","article-title":"Compliance with medical treatments of glaucoma","volume":"1","author":"Weinreb","year":"1992","unstructured":"12. Weinreb RN. Compliance with medical treatments of glaucoma. J Glaucoma. 1992;1:134-136.","journal-title":"J Glaucoma"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrd4239","article-title":"2013 FDA drug approvals","volume":"13","author":"Mullard","year":"2014","unstructured":"13. Mullard A. 2013 FDA drug approvals. Nat Rev Drug Discov. 2014;13:85-89.","journal-title":"Nat Rev Drug Discov"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10792-019-01194-6","article-title":"Real-life experience of using brinzolamide\/brimonidine fixed drop combination in a tertiary glaucoma centre","volume":"40","author":"K\u00f3thy","year":"2020","unstructured":"14. K\u00f3thy P, Holl\u00f3 G. Real-life experience of using brinzolamide\/brimonidine fixed drop combination in a tertiary glaucoma centre. Int Ophthalmol. 2020;40:377-383.","journal-title":"Int Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s12325-014-0168-y","article-title":"Randomized trial of brinzolamide\/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension","volume":"31","author":"Gandolfi","year":"2014","unstructured":"15. Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T. Randomized trial of brinzolamide\/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31:1213-1227.","journal-title":"Adv Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/OPTH.S231402","article-title":"Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide\/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension","volume":"14","author":"Wang","year":"2020","unstructured":"16. Wang N, Lu DW, Pan Y, Astakhov Y, Iureva T, Adewale A, Walker TM. Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide\/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension. Clin Ophthalmol. 2020;14:221-230.","journal-title":"Clin Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.5301\/ejo.5000826","article-title":"Comparison of dorzolamide\/timolol vs brinzolamide\/brimonidine fixed combination therapy in the management of primary open-angle glaucoma","volume":"27","author":"Kozobolis","year":"2017","unstructured":"17. Kozobolis V, Panos GD, Konstantinidis A, Labiris G. Comparison of dorzolamide\/timolol vs brinzolamide\/brimonidine fixed combination therapy in the management of primary open-angle glaucoma. Eur J Ophthalmol. 2017;27:160-163.","journal-title":"Eur J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s10384-019-00673-8","article-title":"Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series","volume":"63","author":"HJ","year":"2019","unstructured":"18. Joh HJ, Jin SW. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series. Jpn J Ophthalmol. 2019;63:322-327.","journal-title":"Jpn J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3341\/kjo.2019.0094","article-title":"Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma","volume":"34","author":"Wy","year":"2020","unstructured":"19. Wy S, Kim YK, Jeoung JW, Park KH, Ha A. Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma. Korean J Ophthalmol. 2020;34:19-26.","journal-title":"Korean J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40123-018-0150-x","article-title":"Brinzolamide\/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens","volume":"7","author":"Moosavi","year":"2018","unstructured":"20. Moosavi R, Ansari E. Brinzolamide\/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens. Ophthalmol Ther. 2018;7:397-403.","journal-title":"Ophthalmol Ther"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:02:46Z","timestamp":1721998966000},"score":1,"resource":{"primary":{"URL":"https:\/\/oftalmoloji.org\/articles\/doi\/tjo.galenos.2021.25488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,1]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2021.25488","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}